Lifordi Immunotherapeutics Bolsters Leadership with Appointment of New Chief Medical Officer

Lifordi Immunotherapeutics has appointed Matthew W. McClure, M.D., as its new Chief Medical Officer, marking a significant strategic move in the company's mission to develop innovative antibody-drug conjugates (ADCs) for autoimmune and inflammatory disorders.

Dr. McClure brings extensive clinical development experience, having led clinical trials at multiple biotechnology companies including Aligos Therapeutics, Second Genome, and Alios BioPharma. His appointment comes at a critical juncture as Lifordi prepares to advance its lead candidate, LFD-200, into Phase 1 clinical trials in mid-year 2025.

The company's ADC platform targets VISTA, a cell surface protein predominantly expressed on immune cells. Preclinical studies of LFD-200 have demonstrated promising characteristics, including a short serum half-life, long immune cell residency, and the ability to deliver immunosuppressive treatments without systemic toxicity.

Lifordi's innovative approach could potentially revolutionize treatment strategies for autoimmune conditions across multiple medical disciplines, including rheumatology, gastroenterology, pulmonology, and dermatology. By leveraging the targeted delivery mechanism, the company aims to overcome traditional limitations of steroid treatments.

Dr. McClure's expertise is expected to be instrumental in translating the company's preclinical research into clinical development, with the potential to offer new therapeutic options for patients suffering from challenging autoimmune diseases.